<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Voss G</submitter><funding>Vetenskapsrådet</funding><funding>Kungliga Fysiografiska Sällskapet i Lund</funding><funding>Prostatacancerfonden</funding><funding>Cancerfonden</funding><pagination>1412-1424</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC8522694</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>27(11)</volume><pubmed_abstract>Even though microRNAs have been viewed as promising biomarkers for years, their clinical implementation is still lagging far behind. This is in part due to the lack of RT-qPCR technologies that can differentiate between microRNA isoforms. For example, A-to-I editing of microRNAs through adenosine deaminase acting on RNA (ADAR) enzymes can affect their expression levels and functional roles, but editing isoform-specific assays are not commercially available. Here, we describe RT-qPCR assays that are specific for editing isoforms, using microRNA-379 (miR-379) as a model. The assays are based on two-tailed RT-qPCR, and we show them to be compatible both with SYBR Green and hydrolysis-based chemistries, as well as with both qPCR and digital PCR. The assays could readily detect different miR-37</pubmed_abstract><journal>RNA (New York, N.Y.)</journal><pubmed_title>Quantification of microRNA editing using two-tailed RT-qPCR for improved biomarker discovery.</pubmed_title><pmcid>PMC8522694</pmcid><funding_grant_id>CAN 2017/559</funding_grant_id><funding_grant_id>VR-MH 2018-03125</funding_grant_id><funding_grant_id>40526</funding_grant_id><pubmed_authors>Voss G</pubmed_authors><pubmed_authors>Edsjo A</pubmed_authors><pubmed_authors>Ceder Y</pubmed_authors><pubmed_authors>Bjartell A</pubmed_authors></additional><is_claimable>false</is_claimable><name>Quantification of microRNA editing using two-tailed RT-qPCR for improved biomarker discovery.</name><description>Even though microRNAs have been viewed as promising biomarkers for years, their clinical implementation is still lagging far behind. This is in part due to the lack of RT-qPCR technologies that can differentiate between microRNA isoforms. For example, A-to-I editing of microRNAs through adenosine deaminase acting on RNA (ADAR) enzymes can affect their expression levels and functional roles, but editing isoform-specific assays are not commercially available. Here, we describe RT-qPCR assays that are specific for editing isoforms, using microRNA-379 (miR-379) as a model. The assays are based on two-tailed RT-qPCR, and we show them to be compatible both with SYBR Green and hydrolysis-based chemistries, as well as with both qPCR and digital PCR. The assays could readily detect different miR-37</description><dates><release>2021-01-01T00:00:00Z</release><publication>2021 Nov</publication><modification>2025-04-05T13:44:19.141Z</modification><creation>2025-04-05T13:44:19.141Z</creation></dates><accession>S-EPMC8522694</accession><cross_references><pubmed>34433636</pubmed><doi>10.1261/rna.078867.121</doi></cross_references></HashMap>